Merck, SML3360-5MG, STM2457

Biochem/physiol Actions
Potent and highly selective SAM-binding site METTL3 (MT-A70) m6A methyltransferase inhibitor with anti-AML efficacy in cultures and in vivo.
STM2457 is a potent and highly selective SAM-binding site METTL3 (MT-A70) m6A methyltransferase inhibitor (IC50 = 16.9 nM, Kd = 1.4 nM by SPR, using METTL3-METTL14 complex; no potency toward other RNA/DNA/protein methyltransferases or 486 kinases). STM2457 selectively inhibits human AML proliferation (IC50 = 0.6-10.3 µM) and the clonogenic potential of primary mouse AML, but not normal mouse haematopoietic stem/progenitor or human cord blood CD34+ cells. STM2457 impairs the expansion of AML patient-derived xenografts in mice in vivo (50 mg/kg i.p.) and significantly prolongs the animal′s lifespan. STM2457 is also reported to restrict β-coronavirus replication and spread.